reference/30136678

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/30136678

Outgoing Links

Predicate	Object
contentType	Clinical Trial\|Clinical Trial, Phase II\|Journal Article\|Research Support, U.S. Gov't, P.H.S.
endingPage	1610
issn	1097-0142 0008-543X
issueIdentifier	8
pageRange	1603-1610
publicationName	Cancer
startingPage	1603
hasFundingAgency	http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_b5ad88fdb9d8a30d34a9b7f844c05af4
isSupportedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f835b78b208494ff652af3878cd4bce0
bibliographicCitation	Hellerstedt B, Pienta KJ, Redman BG, Esper P, Dunn R, Fardig J, Olson K, Smith DC. Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen-independent prostate carcinoma. Cancer. 2003 Oct 15;98(8):1603–10. doi: 10.1002/cncr.11686. PMID: 14534875.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ffbc7bd825afeee5ce82d867c6f4bbb6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_81a1a9de58257a4e4a441fab75e645a6 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b95cd85e880130f514efb56eb8bd7a6f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_27e81a2fbc2fd3df35a7b35fbc4b7323 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d226253093136972d6498338fdf72c9e http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e531f3dc0808d964c4bc7b0b0f394667 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_4e49ff521fed8405a1df53d2977314a8 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_eb8efd3fe2c3faa2ecd354d49fa3f154
date	2003-08-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
identifier	https://doi.org/10.1002/cncr.11686 https://pubmed.ncbi.nlm.nih.gov/14534875
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/2771 https://portal.issn.org/resource/ISSN/1097-0142 https://portal.issn.org/resource/ISSN/0008-543X
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Phase II trial of oral cyclophosphamide, prednisone, and diethylstilbestrol for androgen‐independent prostate carcinoma
discusses	http://id.nlm.nih.gov/mesh/M0005485 http://id.nlm.nih.gov/mesh/M0017465 http://id.nlm.nih.gov/mesh/M0026444 http://id.nlm.nih.gov/mesh/M0006357 http://id.nlm.nih.gov/mesh/M0001106
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000627 http://id.nlm.nih.gov/mesh/D011471Q000188
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D000971Q000009 http://id.nlm.nih.gov/mesh/D014407 http://id.nlm.nih.gov/mesh/D011471Q000523 http://id.nlm.nih.gov/mesh/D000818 http://id.nlm.nih.gov/mesh/D011788 http://id.nlm.nih.gov/mesh/D000368 http://id.nlm.nih.gov/mesh/D000728Q000494 http://id.nlm.nih.gov/mesh/D051381 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D011241Q000008 http://id.nlm.nih.gov/mesh/D009376Q000188 http://id.nlm.nih.gov/mesh/D017430Q000097 http://id.nlm.nih.gov/mesh/D003520Q000008 http://id.nlm.nih.gov/mesh/D000284 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D004054Q000008
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9412 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54678486 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8306 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5995 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_fce276cc0efd2412c7dafdbb1e82fcc8 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5865 http://rdf.ncbi.nlm.nih.gov/pubchem/protein/EC_3.4.21.77 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID448537 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2907

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID128926582 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129717275 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129125890

Total number of triples: 68.